Find Emvododstat manufacturers, exporters & distributors on PharmaCompass

PTC299

PTC299

Synopsis, Chemistry

DEVELOPMENTS

3 Drug(s) in Development

3 Drug(s) in Development

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Emvododstat, Ptc299, Ptc-299, 1256565-36-2, Emvododstat [usan], 053qd2i96a

Molecular Formula

C₂₅H₂₀Cl₂N₂O₃

Molecular Weight

467.3 g/mol

InChI Key

SRSHBZRURUNOSM-DEOSSOPVSA-N

FDA UNII

053QD2I96A

Emvododstat is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and antineoplastic activities. Emvododstat targets post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. This inhibits VEGF protein production and decreases its levels in the tumor and bloodstream. In turn, this may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and eventually the induction of tumor cell death. VEGFs are upregulated in a variety of tumor cell types and play key roles during angiogenesis. In addition, emvododstat may enhance the antitumor activity of other chemotherapeutic agents.

1 2D Structure

PTC299

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate

2.1.2 InChI

InChI=1S/C25H20Cl2N2O3/c1-31-18-7-2-15(3-8-18)24-23-20(21-14-17(27)6-11-22(21)28-23)12-13-29(24)25(30)32-19-9-4-16(26)5-10-19/h2-11,14,24,28H,12-13H2,1H3/t24-/m0/s1

2.1.3 InChI Key

SRSHBZRURUNOSM-DEOSSOPVSA-N

2.1.4 Canonical SMILES

COC1=CC=C(C=C1)C2C3=C(CCN2C(=O)OC4=CC=C(C=C4)Cl)C5=C(N3)C=CC(=C5)Cl

2.1.5 Isomeric SMILES

COC1=CC=C(C=C1)[C@H]2C3=C(CCN2C(=O)OC4=CC=C(C=C4)Cl)C5=C(N3)C=CC(=C5)Cl

2.2 Other Identifiers

2.2.1 UNII

053QD2I96A

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-, 4-chlorophenyl Ester, (1s)-2h-pyrido(3,4-b)indole-2-carboxylic Acid

2. Emvododstat

3. Ptc299

2.3.2 Depositor-Supplied Synonyms

1. Emvododstat

2. Ptc299

3. Ptc-299

4. 1256565-36-2

5. Emvododstat [usan]

6. 053qd2i96a

7. Emvododstat [inn]

8. Emvododstat [who-dd]

9. Schembl8509210

10. Chembl4650336

11. Gtpl11421

12. 1219951-09-3

13. 2h-pyrido(3,4-b)indole-2-carboxylic Acid, 6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-, 4-chlorophenyl Ester, (1s)-

14. Ex-a5798

15. At24059

16. Hy-124593

17. Cs-0087039

18. 4-chlorophenyl (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2h-pyrido(3,4-b)indole-2-carboxylate

19. 4-chlorophenyl (s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indole-2-carboxylate

2.4 Create Date

2010-12-13

3 Chemical and Physical Properties

Molecular Formula	C₂₅H₂₀Cl₂N₂O₃
Molecular Weight	467.3 g/mol
XLogP3	6.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	4
Exact Mass	466.0850979 g/mol
Monoisotopic Mass	466.0850979 g/mol
Topological Polar Surface Area	54.6 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	651
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.

5 Pharmacology and Biochemistry

5.1 Pharmacology

PTC299 demonstrated a broad range of activity in blocking VEGF synthesis in multiple tumor types, including breast, cervical, colorectal, fibrosarcoma, gastric, lung, melanoma, neuroblastoma, ovarian, pancreatic, prostate and renal cell cancer lines. PTC299 as a monotherapy significantly reduced VEGF concentrations in tumors and plasma, reduced tumor blood vessel density, and substantially impeded tumor progression.

5.2 Mechanism of Action

PTC299 was designed to inhibit VEGF production in tumors by targeting the post-transcriptional control processes that regulate VEGF formation. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than therapies, such as Avastin or Sutent. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers.